Skip to main content
PureTech Health plc logo

PureTech Health plc — Investor Relations & Filings

Ticker · PRTC ISIN · GB00BPVG5C82 LEI · 213800LVPDNO2Z9T9I39 IL Manufacturing
Open in API
Filings indexed 1,320 across all filing types
Latest filing 2020-06-10 Regulatory Filings
Country GB United Kingdom
Listing IL PRTC

About PureTech Health plc

https://puretechhealth.com/

PureTech Health is a clinical-stage biotherapeutics company dedicated to discovering, developing, and commercializing new classes of medicine for devastating diseases. The company's research and development engine focuses on advancing novel treatments by enhancing on-target efficacy, improving tolerability, or enabling oral administration of therapeutics with validated mechanisms. Its pipeline includes wholly-owned therapeutic candidates targeting a range of conditions, including idiopathic pulmonary fibrosis, neuropsychiatric disorders, and various cancers.

Recent filings

Filing Released Lang Actions
Second Price Monitoring Extn
Regulatory Filings Classification · 98% confidence The document is very short (1377 characters) and begins with 'RNS Number : 5567P', indicating it is a regulatory news service announcement from the London Stock Exchange. The content describes a 'Second Price Monitoring Extension' for a security, which is a specific operational notice related to trading halts or volatility controls. This type of miscellaneous, non-standard regulatory announcement that doesn't fit the specific categories like ER, 10-K, or DIV is best classified under the general regulatory filing fallback category, RNS (Regulatory Filings).
2020-06-10 English
Price Monitoring Extension
Regulatory Filings Classification · 99% confidence The document is very short (1360 characters) and explicitly states it is providing 'Additional information' via an 'RNS Number'. The content discusses a 'Price Monitoring Extension' for an auction call period on the London Stock Exchange. This is a general regulatory announcement concerning trading mechanics, not a specific financial report (like 10-K, IR, or ER). Since it is a general regulatory announcement provided via RNS, and it doesn't fit any other specific category (like DIRS, DIV, or MANG), the most appropriate classification is the general Regulatory Filings fallback category.
2020-06-10 English
Positive Data from Vedanta IBD Clinical Studies
Earnings Release Classification · 99% confidence The document begins with an 'RNS Number' and is dated June 9, 2020. It contains an announcement from PureTech Health plc regarding positive topline data from Phase 1 studies for a drug candidate (VE202) developed by its Founded Entity, Vedanta Biosciences. It also mentions financing updates ($12 million additional capital) and intellectual property news (European patents). This structure—a brief announcement of significant, non-periodic corporate news (clinical trial results, financing, IP) released via the London Stock Exchange's RNS system—is characteristic of a general regulatory announcement. Since it is not a full financial report (10-K, IR), a specific earnings release (ER), or a proxy statement (DEF 14A), the most appropriate classification is the general regulatory filing category, RNS, as it serves as a primary information provider announcement. Q2 2020
2020-06-09 English
Positive FDA Feedback on Follica
Regulatory Filings Classification · 100% confidence The document begins with 'RNS Number : 8994O' and is dated '04 June 2020'. It details an announcement from PureTech Health plc regarding its Founded Entity, Follica, receiving positive feedback from the FDA to advance a drug program into Phase 3 development. This format—a brief announcement disseminated via the RNS system, often containing press release content—is characteristic of a general regulatory announcement that doesn't fit a specific financial report category like 10-K, ER, or IR. Since it is a formal, non-standard regulatory update distributed through the LSE's news service (RNS), the most appropriate classification is the general regulatory filing category.
2020-06-04 English
Gelesis Approved to Market Plenity in Europe
Regulatory Filings Classification · 100% confidence The document begins with 'RNS Number : 6078O' and is clearly formatted as a regulatory news service announcement from the London Stock Exchange (LSE). The content details an announcement by PureTech Health plc regarding its Founded Entity, Gelesis, receiving a CE Mark approval for its product Plenity in Europe. This type of broad, immediate corporate news release, especially one originating from the RNS system, fits best under the general 'Regulatory Filings' category, which serves as a fallback for official announcements that aren't specific financial reports (like 10-K, ER, IR) or specific corporate actions (like DIV, DIRS, CAP). Since it is an announcement of a regulatory/commercial milestone rather than a financial report or a proxy statement, RNS is the most appropriate classification.
2020-06-02 English
PRTC Targets COVID-19 Post-Recovery Complications
Legal Proceedings Report Classification · 99% confidence The document begins with 'RNS Number : 1410O' and is dated May 28, 2020. It announces a specific corporate development regarding the advancement of a drug candidate (LYT-100) for COVID-19 related complications. The structure, including the RNS header and the nature of the announcement (a press release detailing business updates, clinical trial plans, and forward-looking statements), strongly indicates a regulatory news service release. Since this is a general, time-sensitive announcement that doesn't fit the specific categories like Earnings Release (ER), Capital Update (CAP), or Director's Dealing (DIRS), the most appropriate classification is the general regulatory filing/announcement category, RNS.
2020-05-28 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.